$700.22
Value $260B
Thermo Fisher ScientificvsEntrada Therapeutics
TMO and TRDA stock compared: price, dividend, valuation and results, from SEC filings.
+0.11%
$5.09
Value $195M
Thermo Fisher Scientific (TMO) has a market value of $260B and Entrada Therapeutics (TRDA) $195M. Over the last year, with dividends, TMO moved +19.5% and TRDA -36.5%. Dividend yield: TMO 0.26%, TRDA none.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
TMO$260B
TRDA$195M
TMO is 1,335 times TRDA
Revenue, 12 months
TMO$47.4B
TRDA$4.0M
TMO is 11,906 times TRDA
Net income, 12 months
TMO$7.1B
TRDA-$161M
Operating margin
TMO17.9%
TRDA-4,303.8%
4,321.7 points apart
ROIC
TMO8.2%
TRDA-50.1%
58.3 points apart
P/E
TMO36.8
TRDA–
Dividend yield
TMO0.3%
TRDA0.0%
0.3 points apart
5-year return
TMO+11.8%
TRDA-84.3%
96.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
TMO+11.8%
TRDA-84.3%
| Period | TMOWith dividends | TRDAWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +19.5%Price +19.1% | -36.5%Price -36.5% |
| 3 years since November 13, 2023 | +58.8%+16.7% a yearPrice +57.3% | -68.9%-32.3% a yearPrice -68.9% |
| 5 years since November 12, 2021 | +11.8%+2.3% a yearPrice +10.2% | -84.3%-30.9% a yearPrice -84.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
TMOThermo Fisher ScientificTRDAEntrada Therapeutics
Valuation
TMOTRDA| Price | $700.22 | $5.09 |
|---|---|---|
| Market value | $260B | $195M |
| Enterprise value (EV) | $295B | $1.9M |
| P/E | 36.8 | – |
| P/E, 5-year median | 32.7 | – |
| P/B | 4.8 | 1.0 |
| EV/EBIT | 34.9 | – |
| Free cash flow yield | 2.9% | – |
Results and growth
TMOTRDA| Revenue, 12 months | $47.4B | $4.0M |
|---|---|---|
| Net income, 12 months | $7.1B | -$161M |
| Free cash flow, 12 months | $7.6B | -$136M |
| Earnings per share, 12 months | $18.96 | -$3.84 |
| Revenue growth, year on year | 3.9% | -87.9% |
| Revenue growth a year, past | +6.7%over 5 years | -55.6%over 2 years |
| EPS growth a year, past | +2.1%over 5 years | – |
Margins and returns on capital
TMOTRDA| Gross margin | – | – |
|---|---|---|
| Operating margin | 17.9% | -4,303.8% |
| Net margin | 14.9% | -4,058.0% |
| ROIC | 8.2% | -50.1% |
| ROE | 13.4% | -59.8% |
Balance sheet
TMOTRDA| Cash | $6.1B | $193M |
|---|---|---|
| Total debt | $41.4B | $47M |
| Net debt / EBITDA | 3.7 | – |
| Interest cover | 5.5× | – |
Dividends and buybacks
TMOTRDA| Dividend yield | 0.3% | – |
|---|---|---|
| Dividend per share, 12 months | $1.84 | – |
| Dividend growth a year, past | +14.3%over 5 years | – |
| Buyback yield | 1.2% | – |
| Shareholder yield | 1.4% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, Thermo Fisher Scientific or Entrada Therapeutics?
By market value, Thermo Fisher Scientific ($260B) is about 1,334.9 times Entrada Therapeutics ($195M), at today's prices.
How did TMO and TRDA stock do over the last 5 years?
Since November 12, 2021, TMO's price moved +10.2% and TRDA's -84.3%. With dividends: TMO +11.8% (+2.3% a year), TRDA -84.3% (-30.9% a year). Past returns do not predict future ones.
Which pays the higher dividend, TMO or TRDA?
The dividend yield at today's price is 0.26% for Thermo Fisher Scientific and none for Entrada Therapeutics. Over the last twelve months they paid $1.84 and – per share.
Which has the higher profit margins, Thermo Fisher Scientific or Entrada Therapeutics?
Over the last twelve months, the net margin was 14.9% for Thermo Fisher Scientific and -4,058.0% for Entrada Therapeutics, and the operating margin 17.9% and -4,303.8%. Revenue was $47.4B and $4.0M.
Which is the better investment, Thermo Fisher Scientific or Entrada Therapeutics?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.